Mirae Asset Global Investments’s Taysha Gene Therapies TSHA Stock Holding History

Mirae Asset Global Investments’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87.5K	Sell	12,852 -1,435	-10%	-$8.49K	﹤0.01%	1261
2026 Q1	$63.9K	Buy	14,287 +976	+7%	+$4.54K	﹤0.01%	1251
2025 Q4	$73.2K	Buy	13,311 +2,765	+26%	+$13.4K	﹤0.01%	1316
2025 Q3	$34.5K	Buy	10,546 +443	+4%	+$1.25K	﹤0.01%	1405
2025 Q2	$23.3K	Buy	10,103 +3,731	+59%	+$8.11K	﹤0.01%	1376
2025 Q1	$12.3K	Sell	6,372 -457	-7%	-$764	﹤0.01%	1450
2024 Q4	$12K	Sell	6,829 -583	-8%	-$1.21K	﹤0.01%	1492
2024 Q3	$15.3K	Buy	7,412 +1,829	+33%	+$4.01K	﹤0.01%	1466
2024 Q2	$12.1K	Buy	+5,583	New	+$16.2K	﹤0.01%	1443

Other funds holding TSHA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

AWM

Affinity Wealth Management Wilmington, Delaware $776M AUM 43.59% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Mirae Asset Global Investments's TSHA Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Taysha Gene Therapies (TSHA) stake by 10% in Q2 2026, selling an estimated $8.49K and leaving 12,852 shares worth $87.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1261.

Mirae Asset Global Investments first reported a position in TSHA in Q2 2024 and has held it in 9 quarters since. 61 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Mirae Asset Global Investments held 12,852 shares of Taysha Gene Therapies worth $87.5K as of Q2 2026.
Mirae Asset Global Investments sold 1,435 Taysha Gene Therapies shares in Q2 2026, an estimated $8.49K.
Taysha Gene Therapies made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1261 holding.
Mirae Asset Global Investments first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 9 quarters since.
61 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.